Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 2, 2009, Pages

  Giachini, Fernanda R C ^a,b   Zemse, Saiprasad M ^a   Carneiro, Fernando S ^a,b   Lima, Victor V ^a   Carneiro, Zidonia N ^a   Callera, Glaucia E ^c   Ergul, Adviye ^a   Webb, R Clinton ^a   Tostes, Rita C ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Blood pressure; Tumor necrosis factor ; Vascular reactivity

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; INTERLEUKIN 10; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ENDOTHELIN; ENDOTHELIN B RECEPTOR; FLAVONOID; PEPTIDE FRAGMENT; PROTEIN KINASE INHIBITOR; PYRROLIDINE DERIVATIVE; RECOMBINANT PROTEIN; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE];

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME ACTIVATION; KNOCKOUT MOUSE; MALE; MESENTERIC ARTERY; MESENTERY BLOOD VESSEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; UPREGULATION; VASCULAR RING; WILD TYPE; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GENETICS; HUMAN; INFUSION PUMP; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME; VASOCONSTRICTION;

ANIMALS; AORTA; BLOOD PRESSURE; ENDOTHELIN-1; ENDOTHELINS; FLAVONOIDS; HUMANS; INFUSION PUMPS, IMPLANTABLE; INTERLEUKIN-10; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION;

EID: 61949143689     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00251.2008     Document Type: Article

References (52)

1. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 55: 241-269, 2003.
2. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Melfi F, Mussi A, Basolo F, Fontanini G. Tumour necrosis factor-a: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med 17: 887-892, 2006.
3. Chen S, Kapturczak MH, Wasserfall C, Glushakova OY, Campbell- Thompson M, Deshane JS, Joseph R, Cruz PE, Hauswirth WW, Madsen KM, Croker BP, Berns KI, Atkinson MA, Flotte TR, Tisher CC, Agarwal A. Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway. Proc Natl Acad Sci USA 102: 7251-7256, 2005.
4. Corder R, Carrier M, Khan N, Klemm P, Vane JR. Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Car- diovasc Pharmacol 26 Suppl 3: S56-S58, 1995.
5. D'Angelo G, Adam LP. Inhibition of ERK attenuates force development by lowering myosin light chain phosphorylation. Am J Physiol Heart Circ Physiol 282: H602-H610, 2002.
6. PHOX phosphorylation through a decrease in ERK1/2 activity. FASEB J 20: 1504 -1506, 2006.
7. Daou GB, Srivastava AK. Reactive oxygen species mediate endothelin- 1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells. Free Radic Biol Med 37: 208-215, 2004.
8. Davis JR, Giardina JB, Green GM, Alexander BT, Granger JP, Khalil RA. Reduced endothelial NO-cGMP vascular relaxation pathway during TNF-α-induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol 282: R390-R399, 2002.
9. Dokka S, Shi X, Leonard S, Wang L, Castranova V, Rojanasakul Y. Interleukin-10-mediated inhibition of free radical generation in macro- phages. Am J Physiol Lung Cell Mol Physiol 280: L1196-L1202, 2001.
10. Finsnes F, Skjonsberg OH, Lyberg T, Christensen G. Endothelin-1 production is associated with eosinophilic rather than neutrophilic airway inflammation. Eur Respir J 15: 743-750, 2000.
11. 133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells. J Biol Chem 281: 31647-31658, 2006.
12. Giachini FR, Callera GE, Carneiro FS, Tostes RC, Webb RC. Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors? Expert Opin Ther Targets 12: 327-339, 2008.
13. Grantcharova E, Reusch HP, Beyermann M, Rosenthal W, Oksche A. Endothelin A and endothelin B receptors differ in their ability to stimulate ERK1/2 activation. Exp Biol Med (Maywood) 231: 757-760, 2006.
14. Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S, McNeil T, Bigler M, Roncarolo MG, Coffman RL. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen- presenting cells. J Immunol 162: 1723-1729, 1999.
15. Gunnett CA, Heistad DD, Berg DJ, Faraci FM. IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am J Physiol Heart Circ Physiol 279: H1555-H1562, 2000.
16. Gunnett CA, Heistad DD, Faraci FM. Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. Diabetes 51: 1931-1937, 2002.
17. Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, Cher- outre H, Fowell DJ, Binder S, Tsao B, Locksley RM, Moore KW, Kronenberg M. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 185: 2101-2110, 1997.
18. Hohlfeld T, Klemm P, Thiemermann C, Warner TD, Schror K, Vane JR. The contribution of tumour necrosis factor-a and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol 116: 3309 -3315, 1995.
19. Ishihata A, Tasaki K, Katano Y. Involvement of p44/42 mitogen- activated protein kinases in regulating angiotensin II- and endothelin-1- induced contraction of rat thoracic aorta. Eur J Pharmacol 445: 247-256, 2002.
20. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy 2: 257-265, 2003.
21. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. Endothelin- mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 140: 4659-4668, 1999.
22. Je HD, Gangopadhyay SS, Ashworth TD, Morgan KG. Calponin is required for agonist-induced signal transduction-evidence from an anti- sense approach in ferret smooth muscle. J Physiol 537: 567-577, 2001.
23. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46: 82-86, 2005.
24. Leghmari K, Contreras X, Moureau C, Bahraoui E. HIV-1 Tat protein induces TNF-α and IL-10 production by human macrophages: differential implication of PKC-βII and -8 isozymes and MAP kinases ERK1/2 and p38. Cell Immunol 254: 46-55, 2008.
25. Leinweber BD, Leavis PC, Grabarek Z, Wang CL, Morgan KG. Extracellular regulated kinase (ERK) interaction with actin and the cal- ponin homology (CH) domain of actin-binding proteins. Biochem J 344: 117-123, 1999.
26. Luscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Buhler FR. Interaction between endothe- lin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 66: 1088 -1094, 1990.
27. Mazighi M, Pelle A, Gonzalez W, Mtairag el M, Philippe M, Henin D, Michel JB, Feldman LJ. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am J Physiol Heart Circ Physiol 287: H866-H871, 2004.
28. Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk HD. Differential regulation of monocytic tumor necrosis factor-a and interleukin-10 expression. Eur J Immunol 26: 1580-1586, 1996.
29. Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-convert- ing enzyme 1 in endothelial cells. J Allergy Clin Immunol 105: 333-338, 2000.
30. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H. Plasma interleukin-6 and tumor necrosis factor-a can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 30: 541-548, 2007.
31. Niiro H, Otsuka T, Ogami E, Yamaoka K, Nagano S, Akahoshi M, Nakashima H, Arinobu Y, Izuhara K, Niho Y. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun 250: 200-205, 1998.
32. Nonaka-Sarukawa M, Okada T, Ito T, Yamamoto K, Yoshioka T, Nomoto T, Hojo Y, Shimpo M, Urabe M, Mizukami H, Kume A, Ikeda U, Shimada K, Ozawa K. Adeno-associated virus vector-mediated systemic interleukin-10 expression ameliorates hypertensive organ damage in Dahl salt-sensitive rats. J Gene Med 10: 368-374, 2008.
33. Park PH, McMullen MR, Huang H, Thakur V, Nagy LE. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-a (TNF-α) expression via ERK1/2 activation and Egr-1 expression: role of TNF-α in adiponectin-stimulated interleukin-10 production. J Biol Chem 282: 21695-21703, 2007.
34. Quaschning T, Kocak S, Bauer C, Neumayer HH, Galle J, Hocher B. Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. Nephrol Dial Transplant 18: 479 -483, 2003.
35. Rokolya A, Singer HA. Inhibition of CaM kinase II activation and force maintenance by KN-93 in arterial smooth muscle. Am J Physiol Cell Physiol 278: C537-C545, 2000.
36. Russell A, Watts S. Vascular reactivity of isolated thoracic aorta of the C57BL/6J mouse. J Pharmacol Exp Ther 294: 598-604, 2000.
37. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 274: 31868-31874, 1999.
38. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond) 105: 45-50, 2003.
39. Suttles J, Milhorn DM, Miller RW, Poe JC, Wahl LM, Stout RD. CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (IL)-4 and IL-10 anti-inflammatory action. J Biol Chem 274: 5835-5842, 1999.
40. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 88: 877-887, 2001.
41. b endothelin antagonist ameliorates systemic inflammation in a murine model of acute hemorrhagic pancreatitis. Surgery 122: 443-450, 1997.
42. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 288: H1016-H1021, 2005.
43. Wagner EM. TNF-α-induced bronchial vasoconstriction. Am J Physiol Heart Circ Physiol 279: H946-H951, 2000.
44. Wen Y, Wang JY, Liu P. [Tumor necrosis factor-a enhances the effect of endothelin on renal vasoconstriction in isolated perfused rat kidney]. Zhonghua Gan Zang Bing Za Zhi 11: 583-585, 2003.
45. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, Warner TD. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol 55: 902-909, 1999.
46. Woods M, Wood EG, Mitchell JA, Warner TD. Signal transduction pathways involved in cytokine stimulation of endothelin-1 release from human vascular smooth muscle cells. J Cardiovasc Pharmacol 36: S407-S409, 2000.
47. Xu J, Zhong NS. The interaction of tumour necrosis factor a and endothelin-1 in pathogenetic models of asthma. Clin Exp Allergy 27: 568-573, 1997.
48. Yogi A, Callera GE, Montezano AC, Aranha AB, Tostes RC, Schiffrin EL, Touyz RM. Endothelin-1, but not ANG II, activates MAP kinases through c-Src independent Ras-Raf dependent pathways in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 27: 1960-1967, 2007.
49. Zemse SM, Hilgers RH, Simkins GB, Rudic RD, Webb RC. Restoration of endothelin-1-induced impairment in endothelium-dependent relaxation by interleukin-10 in murine aortic rings. Can J Physiol Pharmacol 86: 557-565, 2008.
50. Zemse SM, Hilgers RH, Webb RC. Interleukin-10 counteracts impaired endothelium-dependent relaxation induced by ANG II in murine aortic rings. Am J Physiol Heart Circ Physiol 292: H3103-H3108, 2007.
51. Zhao RZ, Chen X, Yao Q, Chen C. TNF-α induces interleukin-8 and endothelin-1 expression in human endothelial cells with different redox pathways. Biochem Biophys Res Commun 327: 985-992, 2005.
52. Zhou Y, Dirksen WP, Zweier JL, Periasamy M. Endothelin-1- induced responses in isolated mouse vessels: the expression and function of receptor types. Am J Physiol Heart Circ Physiol 287: H573-H578, 2004.